China Pharma Update: Updated Biosimilar Guidelines Released in 2026 — Key Takeaways
On March 15, 2026, the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA, 国家药监局, guójiā yàojiān jú) released the finalized “Updated Technical Guidelines for the Development and Evaluation of Biosimilars (2026 Revision)”, a 54-page document that replaces the 2015 Trial Guidelines. This revision fundamentally tightens clinical comparability standards while unlocking strategic flexibility for global Reference Product (RP) bridging, and extends data exclusivity to 9 years. For foreign executives, these changes reshape the investment thesis for biosimilars (生物类似药, shēngwù lèisì yào) in the world’s second-largest pharmaceutical market.
Core Regulatory Changes in the 2026 Guidelines
The 2026 guidelines represent a significant tightening of the clinical comparability pathway while simultaneously opening up strategic flexibility in development. The most impactful shift is the restriction of indication extrapolation (适应症外推, shìyìngzhèng wàituī). Under the 2015 rules, a biosimilar demonstrating high similarity to the innovator product in quality and non-clinical studies could receive approval for all indications held by the innovator without direct comparative clinical data for each one. This “extrapolation by default” approach was a major time and cost advantage for biosimilar developers.
The updated 2026 framework now explicitly requires a dedicated comparative clinical study for at least one sensitive indication. Specifically, the CDE mandates a confirmatory Phase III equivalent trial for every biosimilar seeking approval in China. While this increases development costs by an estimated 30-40% (roughly RMB 200M / USD 28M per product), it reduces the risk of post-market safety surprises and strengthens the evidence package required for clinician acceptance in a market transitioning towards evidence-based procurement.
Global Integration: Reference Product Selection & Bridging
A major pain point for global biosimilar developers has been the requirement to exclusively use a China-sourced Reference Product (RP) for all comparative studies. The 2026 guideline now formally accepts bridging strategies using US (FDA), EU (EMA), or Japan (PMDA) licensed RPs, provided a robust analytical similarity and functional assay bridging exercise demonstrates no clinically meaningful differences. This aligns China closer with ICH E5/R2 guidelines.
For a foreign executive, this means a single global formulation can be used across development programs. A US biotech can now use its US Phase I PK/PD data to support a China approval via an addendum to the global NDA dossier, slashing time-to-market by 12-18 months. However, this flexibility requires upfront investment in a comparator inventory bridging study. If the non-China RP and China-marketed RP differ significantly in glycosylation profiles or potency, a full bridging clinical trial may still be required by the CDE review committee.
Pricing, VBP, and Biosimilar Naming Strategy
The guidelines are silent on direct pricing, but the attached notice on biosimilar naming (生物类似药命名, shēngwù lèisì yào mìngmíng) carries deep market access implications. The NMPA will now issue a distinct suffix to the INN for all approved biosimilars. This prevents automatic substitution at the pharmacy level unless specifically listed by the National Healthcare Security Administration (NHSA). For foreign firms, the pricing strategy is now bifurcated: compete on volume via the Volume-Based Procurement (VBP, 集中带量采购, jízhōng dàiliàng cǎigòu) program at 70-80% discounts, or compete on value in the out-of-hospital private market where the naming suffix allows for brand differentiation.
The parallel extension of data protection from 6 years to 9 years under the revised Drug Registration Regulation creates a longer window to recoup the higher clinical development costs mandated by the new guidelines. For a biosimilar targeting a market like bevacizumab or trastuzumab, which currently see 5-6 competitors, the extra 3 years of exclusivity—combined with the distinct naming—allows a well-positioned entrant to secure hospital formulary access before generic-style price erosion fully hits.
Comparison Table: 2015 vs. 2026 Biosimilar Framework
| Feature | 2015 Guideline | 2026 Updated Guideline | Business Impact |
|---|---|---|---|
| Reference Product (RP) | China-sourced RP exclusively required | Multi-source RP accepted (US, EU, JP, CN) with bridging study | Easier global strategy, lower bridging costs if planned early |
| Indication Extrapolation | Permissive (no direct clinical data required for each indication) | Restrictive (requires 1 confirmatory Phase III equivalent trial) | Higher Phase III costs (~RMB 200M), stronger evidence package |
| Immunogenicity Assessment | Standard risk-based panels | Enhanced immunogenicity risk assessment (domains, epitope mapping) | Longer development timeline (+6 months) but lower rejection risk |
| Data Protection Period | 6 years | 9 years | Increased ROI predictability, longer window to capture market share |
| Naming Convention | Same INN as innovator | Distinct suffix required for biosimilars | Enables brand differentiation, critical for VBP vs. private market |
Decision Framework for Foreign Executives
If your biosimilar program is in Phase I globally or earlier, choose to align your development plan strictly with the 2026 guidelines now. Establish a single global RP bridging strategy early to avoid duplicate PK/PD studies. This minimizes long-term regulatory risk and aligns your dossier for simultaneous submission in China and your home market.
If your biosimilar is already in Phase III in the US or EU, choose to conduct a focused confirmatory safety/efficacy bridging study in China targeting the most sensitive indication identified by the CDE. This is the fastest path to a 2027-2028 China approval, but requires immediate investment in a local comparator team and CRO capacity.
Critical Compliance Pitfalls
NEXT STEPS
- Conduct a Regulatory Gap Analysis: Review your current biosimilar program (CMC, non-cl
Official Sources
